
    
      The study duration per subject will be 3 months and 1 week maximum. Subjects will be screened
      at visit V1 and will start a 1-week run-in period, during which subjects will ingest 2
      capsules of placebo 3 times a day.

      The subjects will then be randomized to receive the investigational medical device or placebo
      (1:1) for a 3 months product intake period.
    
  